Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q3 2026
Net profit, assets, equity and cash flow for Q3 2026, against the same period a year earlier, from the published financial statements. Consolidated figures cover the 9 months to 30 September 2026; the comparison is with the same months a year earlier, from the same disclosure.
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q3 2026 was about 180 million EGP, up +73.5% from 104 million EGP in Q3 2025.
- Total assets at the end of Q3 2026 were about 1.43 billion EGP, and shareholders' equity about 918 million EGP.
- Operating cash flow for Q3 2026 was positive at 81.75 million EGP.
Key lines against the same period a year earlier
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Consolidated figures cover the 9 months to 30 September 2026; the comparison is with the same months a year earlier, from the same disclosure.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Fiscal year 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy